Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management

This publication has 24 references indexed in Scilit:

• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• Cholesterol Reduction Yields Clinical Benefit
  Circulation, 1998
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Small, Dense Low-Density Lipoprotein Particles and Coronary Heart Disease Risk
  Published by American Medical Association (AMA) ,1996
• Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials
  Controlled Clinical Trials, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
  JAMA, 1993
• The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.
  Circulation, 1990